Life Sciences Declaration (English Version)

In the broader healthcare system, life sciences are a key strategic lever. They translate scientific progress into better outcomes for patients while making healthcare more efficient and sustainable.

Take action now to safeguard health, prosperity and strategic autonomy in Belgium

In the broader healthcare system, life sciences are a key strategic lever. They translate scientific progress into better outcomes for patients while making healthcare more efficient and sustainable.

The international context, however, is rapidly evolving. Global competition for investment, talent and production is intensifying, while Innovation keeps accelerating. Countries are making clear, strategic choices, aligning research, healthcare, and industrial policy around a coherent long-term vision.

Belgium must do the same through fast and bold political choices.

For many decades, our country has been leading in world-class research, a strong clinical environment, a dense network of partnerships and a highly innovative biopharma sector. Together, they form the foundations of a unique “virtuous circle”.

What is missing today is not potential but a clear, holistic approach to strengthen and anchor this ecosystem for the future.

This is the purpose of the Life Sciences Declaration.

It calls for coherent action that accelerates innovation to patients and reinforces Belgium’s position as a leading hub for life sciences in Europe and beyond.

Over the next six months, we will turn ambition into action, through a dynamic process that mobilises our ecosystem to endorse this declaration.

The future of life sciences in Belgium will be shaped by the choices we make today

LIFE SCIENCES DECLARATION

ACT NOW TO SECURE HEALTH, PROSPERITY AND STRATEGIC AUTONOMY IN BELGIUM

The strength of Belgium’s healthcare system, scientific excellence and economic future depends on the choices
policymakers make today.

Life sciences are not a distant promise. They are a present-day engine for better health, sustainable care and longterm growth. When innovation is enabled, patients benefit, researchers thrive and healthcare professionals can
deliver better outcomes. When innovation is constrained, it moves elsewhere. Investment follows. Access to care
is delayed, and society pays the price.

Belgium now faces a clear choice: restore the positive cycle of life sciences innovation or accept gradual decline.

A VIRTUOUS CIRCLE THAT BENEFITS EVERYONE

A well-functioning innovation cycle, from discovery to clinical practice and reinvestment, creates a virtuous circle
with tangible benefits for everyone:

  • Patients gain faster and more equitable access to innovative, life-saving treatments.
  • Healthcare professionals can rely on better therapeutic tools, improving outcomes and quality of care.
  • Researchers and academics work in an environment that attracts funding, talent and global collaboration.
  • Our health system becomes more sustainable as better outcomes reduce long-term costs.
  • Our economy grows through high-value jobs, R&D investment and exports.
  • Belgium strengthens its strategic autonomy, reducing dependence on external innovations and supply chains.

When this cycle weakens, innovation slows down, investment relocates and access to care is postponed. When it
weakens, everyone loses: patients wait, health outcomes deteriorate, healthcare pressures rise, and Belgium’s
competitiveness erodes.

BELGIUM IS AT A TIPPING POINT

Globally, investment in life sciences is accelerating at unprecedented speed. Other countries, especially the US
and China are making deliberate choices to attract research, clinical trials and manufacturing.

Without decisive action Belgium risks evolving from a pharma valley into a pharma desert:

  • Breakthroughs will increasingly be developed and tested elsewhere.
  • Belgian patients will wait longer for new treatments.
  • Researchers will face shrinking opportunities and brain drain.
  • Healthcare budgets will remain under pressure, without long-term gains.

RESTORING THE VIRTUOUS CIRCLE

Life sciences innovation is long-term, costly and inherently risky. It only succeeds when the entire chain is
supported:

  • Fair valuation and timely access determine whether we can invest.
  • Predictable and competitive frameworks determine whether we dare to invest
  • Revenues from successful innovation fuel reinvestment, new discoveries and better care.

Breaking this cycle harms patients, undermines science, weakens healthcare delivery and ultimately increases
public costs.

OUR CALL TO POLICYMAKERS

We urge Belgian decision-makers to act now on four priorities that deliver clear and measurable benefits:

  1. Stimulate innovation: Strengthen intellectual property protection and safeguard incentives for research
    and development.
    Benefit: More research in Belgium, stronger academic–industry collaboration, and high-value jobs.
     
  2. Recognise healthcare as an investment: Treat healthcare spending, including innovative medicines, as
    an investment in outcomes, not a cost to be minimised.
    Benefit: More sustainable healthcare and better long-term results for patients.
     
  3. Accelerate patient access: Simplify, align and speed up access pathways for innovative treatments.
    Benefit: Earlier access, fewer inequalities and more effective use of scientific progress.
     
  4. Restore competitiveness: Reduce unnecessary regulatory complexity and ensure Belgium remains an
    attractive place to develop, test and produce innovation.
    Benefit: Retained talent, stronger investment climate and durable economic growth.

THE COST OF INACTION IS HIGHER

Failing to act does not save money. The cost is higher through delayed care, lost innovation, weakened research
ecosystems and growing strategic dependence.

  • Restoring the positive circle of life sciences innovation delivers:
  • Better health for patients
  • Stronger tools for healthcare professionals
  • A future for scientific excellence
  • A resilient and sustainable Belgian economy

This is a shared responsibility; but leadership must start now.

We choose action.
We choose innovation.
We choose Belgium’s future in life sciences.

Please refer to the Life Sciences Declaration

Sign the Life Sciences Declaration

Number of people who have already signed the Life Sciences Declaration!

1032
Naam Organisatie Functie Ingediend op
Vicky van den Nieuwenhuyzen Servier Benelux Marketing Director CMVD
Sara Deleu KU Leuven Post doctoral researcher
Lut De Baere BOKS vzw voorzitter
Sarah Verhaeghe Amgen Regulatory Affairs
Sabine De Beuf Bristol Myers Squibb Corporate Affairs Director
Collin Frédérique Abbvie Medical Lead Specialty Care
Zehra Taspinar Amgen Medical Project Management Associate
Katy Verhelle az groeninge head of pharmacy
Carine verrees Hairstudio Haarwerker
Charlotte Bertrand PwC Belgium Manager R&D & Quality - Biotech
Geoffrey Marrion Amgen Sales manager
Anouk Devriendt Amgen CRA
Linde Buntinx Anima Research Center Study Lead
Marie-Aline Neveu Forecast Consulting Innovation funding consultant
Kim Viville Firstwave PM
Bryan Holvoet Novartis Medical Lead Oncology
Tine Schepers Novartis MSL
Joke Dekeersmaeker FirstWave Clinical Research Associates
Sarah Van de Velde FirstWave clinical consultancy Clinical Research Manager
Erik Buntinx ANIMA Research bv / ANeuroTech Founding CEO - Leading Principal Investigator
Palms BiOkuris CBO
Els Peeters Gilead Sri. Therapeutic Specialist
Carl Tilling Astellas Pharma Market Access
Aurelie Partouche Astellas Pharma General Manager BeNeLux and Ireland
Luc Somers OncoLogX BV Principal Consultant Patient Access
Voisin Novo nordisk RWE lead
Shanna Hurts Allucent Global regulatory manager
Frederique Van de Velde Sillar Clinical
Sara De Pauw Allucent Global Regulatory Manager
Karen Detournay Novartis Medical Therapeutic Area Lead
Gert Heymans Bristol Myers Squibb Business Unit Director Onco-Hematology
Marc De Vos Itinera CEO
bart steukers agoria CEO
Nadja De Wolf Amgen Sr Corporate & Governmental Affairs Manager
Pauline Bardet Vrije Universiteit Brussel Post-Doc
Leen Tobback Amgen Medical Director
Caroline Akst Abbvie Study start-up lead
Christianna Dewit Amgen Sr. Mgr. Local Study Operations
Koen Straetmans NVGV - ANGR Voorzitter - Président
Bregt Janssens Boehringer Ingelheim Medical Information Manager & Responsible for Information and Publicity
Maida Zivalj VUB
Gert Loriers Janssen-Cilag NV (J&J) Access Intelligence & Strategy Lead
Yannick Vandenplas Amgen BeLux Value and access manager
Katrien Casteleyn Amgen Business Unit Director
Vincent De Cleer Amgen Sr. Sales Mgr
Van Baeveghem Jan Amgen Marketing Lead Inflammation & Rare Diseases
Martin
Stefanie Lepers Oxford Global Resources, contracted partner of Amgen CRA
Atilla Altinok Amgen Global Medical Information
Vanhee Nicolas Amgen Hospital & Wholesaler Manager
Julie Den Hondt Amgen Sr Marketing Associate
PIERRE VANDEPAPELIÈRE Amyl therapeutics CEO
Vanessa Vankerckhoven Idevax CEO
Geert Jannes Fujirebio Europe Business Development Director
Tamara Jarayseh Ghent University Post -doc researcher and project manager
Sema Kaya Sillar clinical Clinical Trial Manager
Kristien bonroy Ucb Partnership and innovation lead
Joost Uitdehaag ATB Therapeutics Head of Research
Nick Geukens KU Leuven Innovation Manager
Tessa Johnson Biovia Community and business development managet
Dorine Sichien Argenx Senior scientist
Gudrun Antoons Biovia Innovation manager
Frank van der Zanden Helmond Biotech-materials Hub BV
Filip Delport Vixen bio Cbo
Jiri Keirsse UCB
Gil Beyen Montis Biosciences CEO
Noraly Vanden Dorpe J&J Senior site manager
Dirk Veelaert Vlaio Advisrur
Tanja Domnina UCB Communications Lead
Frank Zanden Sure Laboratories CEO
Bernard van der Veer KU Leuven Postdoctoral Researcher
H. Sterckx UZ Leuven Diensthoofd Clinical Trial Center (CTC)
Tom Van Lee Bristol Myers Squibb
Paul Perdieus OPHACO Secretary-general
François KANEN CHRN (centre hospitalier régional de Namur PEDIATRE
Olivier Sels Zoetis Regulatory and Compliance Director
Janne Goovaerts AbbVie Clinical Start-Up Specialist
laurence reynaert
Patricia Lanssiers association du diabète Directrice Générale
De Knop Irina Anders Federaal Volksvertegenwoordiger
Willeke Dijkhoffz ZAS CEO
sandrine pollet AbbVie Medical Director
Axel Vanderperre UTOPIA_bxl President
Ann Van Gyseghem Life Sciences Executive
Debruyne Luc Fund Plus Chairman of the board
Frank Beckx Voka CEO
Carinne VIB-KU Leuven Support team member
Michael Storme APB Président
Anneleen Vanbrabant AbbVie Brand Manager
Anton Delbarre Cognaris Chief Economist
Christos Theodoropoulos VIB AI Expert
Filip Dewallens Dewallens & partners Managing partner
Marek Piprek Nucleate Ambassadors Belgium Managing Director
Daan Aeyels Voka Expert Welzijns- en Gezondheidsbeleid
Carla Ramon Garcia Boehringer Ingelheim General Manager & Head of Human Pharma
Luc Adriaenssens APB General Manager
Hilde De Vleeschhauwer Tobeas bv Stafmedewerker
Frank Peeters UPIP-VAPI Voorzitter
Françoise Desmet GSK Market Access Manager
Laurence Hénuset AbbVie QA Manager

Companies/Institutions/Organisations supporting the Life Sciences Declaration

Bristol-Myers-Squibb
UCB-Pharma
Sanofi
Monsana
Almirall
Glaxo
BeMedTech
Biogen-Belgium
BioVille
Biopark-Charleroi
Daiichi-Sankyo
AbbVie
Esperity
Gedeon Richter logo
Ipsen
Eli-Lilly-Benelux
SMA-Belgium
Bayer
Become a member

Schrijf je in op onze nieuwsbrief

Wil je op de hoogte blijven van het reilen en zeilen binnen de farma-industrie, schrijf je dan in op onze nieuwsbrief!